A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Launched by KISSEI PHARMACEUTICAL CO., LTD. · Oct 16, 2019
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Japanese patients
- • Patients diagnosed with idiopathic thrombocytopenic purpura at least 6 months before acquisition of consent
- • Patients with a platelet count averages \<30000/μL during screening period. Each platelet count should not exceed 35000/μL.
- • Patients who have used and failed or who were intolerant at least 1 typical regimen for the treatment of ITP before informed consent (with or without splenectomy)
- Exclusion Criteria:
- • Patients with thrombocytopenia associated with other disease
- • Patients with autoimmune hemolytic anemia
- • Patients with poorly controlled hypertension
- • Patients with a history or active coagulopathy
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong focus on specialty pharmaceuticals, Kissei leverages advanced technologies and rigorous clinical research to create effective treatments in areas such as urology, nephrology, and diabetes management. Committed to enhancing patient outcomes, Kissei collaborates with healthcare professionals and research institutions worldwide, ensuring a comprehensive approach to drug development that aligns with global health standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , Japan
Patients applied
Trial Officials
Yoshitaka Shimizu
Study Director
Kissei Pharmaceutical Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials